H Lundbeck A/S
CSE:HLUN A

Watchlist Manager
H Lundbeck A/S Logo
H Lundbeck A/S
CSE:HLUN A
Watchlist
Price: 32.95 DKK -1.35% Market Closed
Market Cap: 32.8B DKK

H Lundbeck A/S
Investor Relations

Founded in 1915 by Hans Lundbeck, H. Lundbeck A/S has grown from a small trading company into a notable player within the pharmaceutical industry, specializing in the treatment of brain diseases. Over the decades, the company honed its focus on neuroscience, particularly targeting mental health disorders. This specialization has allowed Lundbeck to establish a strong presence in the therapeutic areas of depression, schizophrenia, Alzheimer's, and Parkinson's diseases. The company's operations are grounded in a rigorous commitment to research and development, constantly seeking breakthroughs that can transform mental health treatment. A significant portion of its revenue is channeled back into R&D to maintain its pipeline of innovative pharmaceuticals, ensuring a future driven by new drug discoveries that align with patient needs.

Lundbeck’s revenue streams primarily stem from its portfolio of prescription medicines, marketed globally across numerous countries. The company capitalizes particularly on a few blockbuster drugs, forming strategic alliances and partnerships to expand its reach and efficacy. Through a robust distribution network, Lundbeck effectively channels its products from manufacturing through to consumers, including hospitals and pharmacies. Moreover, the company benefits from strategic collaborations with other pharmaceutical giants, enhancing its footprint in competitive markets. By continually investing in cutting-edge research and leveraging strategic partnerships, Lundbeck maintains its mission of delivering effective central nervous system therapies, ensuring a sustainable growth trajectory.

Show more
Loading
HLUN A
OMX Copenhagen 25

Earnings Calls

2024 Q3
Nov 13, 2024
Show Transcript
Previous
Next
Lundbeck's Revenue Surges with Strategic Brand Growth and Positive Guidance
2024 Q3
Nov 13, 2024

Lundbeck reported a 13% revenue growth for the first nine months of 2024, driven primarily by its strategic brands, which increased 21%. Vyepti and Rexulti led this charge, with Vyepti's revenue up 76% year-over-year. The company raised its revenue growth guidance to 12-14% and adjusted EBITDA growth to 17-20%. Noteworthy developments include advancements in R&D, particularly in the SUNRISE and bexicaserin trials, which bolster confidence in long-term strategies. As of now, Lundbeck maintains a strong market position, with an adjusted gross margin of approximately 88%.

Show Full Analysis

Management

Mr. Charl van Zyl
President & CEO
No Bio Available
Mr. Joerg Hornstein
CFO & Executive VP of Corporate Functions
No Bio Available
Mr. Lars Bang
Executive Vice President of Product Development & Supply
No Bio Available
Dr. Tarek Samad Ph.D.
Senior VP & Head of Research
No Bio Available
Mr. Palle Holm Olesen
Chief Specialist & VP of Investor Relations
No Bio Available
Ms. Tine Ostergaard Hansen
Senior Vice President of Corporate Communications & Public Affairs
No Bio Available
Ms. Dianne Holto
Executive Vice President of People & Culture
No Bio Available
Mr. Ole Chrintz
Senior Vice President of International Markets
No Bio Available
Dr. Rupert Sandbrink M.D., Ph.D.
Senior VP & Head of Clinical Development
No Bio Available
Mr. Bjorn R. Mogensen
Senior Vice President of Group Finance
No Bio Available

Contacts

Address
Valby
Ottiliavej 9
Contacts
+4530832035.0
www.lundbeck.com